Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Global E Online Ltd (GLBE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Global E Online Ltd — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Global E Online Ltd trades at $38.8 (market cap $6.46B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 6.2× Global E Online Ltd's market cap, and Global E Online Ltd is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | GLBE | |
|---|---|---|
Market Cap | $39.89B | $6.46B |
Sector | Health | Technology |
52-Week High | $491.22 | $41.59 |
52-Week Low | $278.09 | $27.54 |
Enterprise Value | $38.15B | $5.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
GLBE trades at $38.48, up 1.69% today, with a bullish technical signal from moving averages. The stock is supported by strong analyst consensus (14 buy ratings) and a recent $500 million share repurchase authorization. Revenue grew to $962.20 million in 2025, with net income of $68.27 million, and the company's acquisition of Passport aims to enhance logistics capabilities. The current price is near the consensus price target of $38.00.
The outlook remains positive driven by e-commerce growth and strategic acquisitions, though high valuation multiples (P/E of 57.43) pose a risk if growth slows. Key opportunities include expanding cross-border services, while risks involve execution of acquisitions and competitive pressures. Earnings have been mixed, with a recent miss in Q1 2026 against expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Global E Online Ltd
Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.
Read more on GLBE →
